SEA0400, a specific Na +/Ca 2+ exchange inhibitor, prevents dopaminergic neurotoxicity in an MPTP mouse model of Parkinson's disease

Neuropharmacology

Volumn 61, Issue 8, 2011, Pages 1441-1451

  Ago, Yukio ^a   Kawasaki, Toshiyuki ^a,b   Nashida, Tetsuaki ^a   Ota, Yuki ^a   Cong, Yana ^a   Kitamoto, Mari ^a   Takahashi, Teisuke ^c   Takuma, Kazuhiro ^a   Matsuda, Toshio ^a  

^a OSAKA UNIVERSITY   (Japan)

^b RIKEN   (Japan)

^c TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Dopamine; Mice; MPTP; Na + Ca 2+ exchanger (NCX); Nitric oxide (NO); Parkinson's disease; SEA0400

Indexed keywords

2 [4 (2,5 DIFLUOROBENZYLOXY)PHENOXY] 5 ETHOXYANILINE; DOPAMINE; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG EFFECT; ENZYME PHOSPHORYLATION; LIPID PEROXIDATION; MALE; MESENCEPHALON; MICROGLIA; MOTOR COORDINATION; MOTOR DYSFUNCTION; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANALYSIS OF VARIANCE; ANILINE COMPOUNDS; ANIMALS; BRAIN; CALCIUM-BINDING PROTEINS; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FREE RADICAL SCAVENGERS; GENE EXPRESSION REGULATION; LIPID PEROXIDATION; MALE; MICE; MICE, INBRED C57BL; MICROFILAMENT PROTEINS; MOTOR ACTIVITY; MPTP POISONING; NEUROPROTECTIVE AGENTS; PHENYL ETHERS; PHOSPHORYLATION; ROTAROD PERFORMANCE TEST; SODIUM-CALCIUM EXCHANGER; TIME FACTORS; TYROSINE; TYROSINE 3-MONOOXYGENASE;

EID: 80053612497     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2011.08.041     Document Type: Article

References (52)

1. Y. Ago, S. Arikawa, M. Yata, K. Yano, M. Abe, K. Takuma, and T. Matsuda Role of prefrontal dopaminergic neurotransmission in glucocorticoid receptor-mediated modulation of methamphetamine-induced hyperactivity Synapse 63 2009 7 14
2. Y. Ago, S. Arikawa, M. Yata, K. Yano, M. Abe, K. Takuma, and T. Matsuda Antidepressant-like effects of the glucocorticoid receptor antagonist RU-43044 are associated with changes in prefrontal dopamine in mouse models of depression Neuropharmacology 55 2008 1355 1363
3. 2+ exchanger: from molecular biology to therapeutic perspectives Pharmacol. Rev. 56 2004 633 654 (Pubitemid 39658464)
4. K. Aquilano, S. Baldelli, G. Rotilio, and M.R. Ciriolo Role of nitric oxide synthases in Parkinson's disease: a review on the antioxidant and anti-inflammatory activity of polyphenols Neurochem. Res. 33 2008 2416 2426
5. 2+ exchange activity in neuronal preparations and cultured rat astrocytes J. Neurochem. 64 1995 2437 2441
6. 2+ homeostasis in hippocampal neurons J. Neurochem. 68 1997 95 105 (Pubitemid 26427296)
7. i homeostasis contributes to the toxicity of nitric oxide in cultured hippocampal neurons J. Neurochem. 69 1997 1882 1889 (Pubitemid 27452733)
8. V. Calabrese, C. Cornelius, E. Rizzarelli, J.B. Owen, A.T. Dinkova-Kostova, and D.A. Butterfield Nitric oxide in cell survival: a janus molecule Antioxid. Redox Signal. 11 2009 2717 2739
9. E. Castañeda, I.Q. Whishaw, and T.E. Robinson Changes in striatal dopamine neurotransmission assessed with microdialysis following recovery from a bilateral 6-OHDA lesion: variation as a function of lesion size J. Neurosci. 10 1990 1847 1854
10. M. Chalimoniuk, N. Lukacova, J. Marsala, and J. Langfort Alterations of the expression and activity of midbrain nitric oxide synthase and soluble guanylyl cyclase in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice Neuroscience 141 2006 1033 1046 (Pubitemid 44066660)
11. J.Y. Choi, E.H. Jang, C.S. Park, and J.H. Kang Enhanced susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in high-fat diet-induced obesity Free Radic. Biol. Med. 38 2005 806 816
12. S.J. Crocker, P.D. Smith, V. Jackson-Lewis, W.R. Lamba, S.P. Hayley, E. Grimm, S.M. Callaghan, R.S. Slack, E. Melloni, S. Przedborski, G.S. Robertson, H. Anisman, Z. Merali, and D.S. Park Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease J. Neurosci. 23 2003 4081 4091 (Pubitemid 36958427)
13. T. Dehmer, J. Lindenau, S. Haid, J. Dichgans, and J.B. Schulz Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo J. Neurochem. 74 2000 2213 2216 (Pubitemid 30217680)
14. Y. Du, Z. Ma, S. Lin, R.C. Dodel, F. Gao, K.R. Bales, L.C. Triarhou, E. Chernet, K.W. Perry, D.L. Nelson, S. Luecke, L.A. Phebus, F.P. Bymaster, and S.M. Paul Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease Proc. Natl. Acad. Sci. U S A 98 2001 14669 14674 (Pubitemid 33121449)
15. D.J. Eve, A.P. Nisbet, A.E. Kingsbury, E.L. Hewson, S.E. Daniel, A.J. Lees, C.D. Marsden, and O.J. Foster Basal ganglia neuronal nitric oxide synthase mRNA expression in Parkinson's disease Brain Res. Mol. Brain Res. 63 1998 62 71 (Pubitemid 28559088)
16. K.B.J. Franklin, and G. Paxinos The Mouse Brain in Stereotaxic Coordinates 1997 Academic Press, Inc. San Diego
17. E.S. Furfine, M.F. Harmon, J.E. Paith, R.G. Knowles, M. Salter, R.J. Kiff, C. Duffy, R. Hazelwood, J.A. Oplinger, and E.P. Garvey Potent and selective inhibition of human nitric oxide synthases J. Biol. Chem. 269 1994 26677 26683
18. H.M. Gao, J. Jiang, B. Wilson, W. Zhang, J.S. Hong, and B. Liu Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease J. Neurochem. 81 2002 1285 1297 (Pubitemid 34809262)
19. H.M. Gao, B. Liu, and J.S. Hong Critical role of microglia NADPH oxidase-derived free radicals in the MPTP model of Parkinson's disease J. Neurosci. 23 2003 1228 1236
20. S.J. Harper, and N. Wilkie MAPKs: new targets for neurodegeneration Expert Opin. Ther. Targets 7 2003 187 200 (Pubitemid 36512020)
21. S. Hayley, S.J. Crocker, P.D. Smith, V. Jackson-Lewis, S. Przedborski, M. Mount, R. Slack, H. Anisman, and D.S. Park Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease J. Neurosci. 24 2004 2045 2053 (Pubitemid 38292818)
22. S. Hunot, F. Boissire, B. Faucheux, B. Brugg, A. Mouatt-Prigent, Y. Agid, and E.C. Hirsch Nitric oxide synthase and neuronal vulnerability in Parkinson's disease Neuroscience 72 1996 355 363 (Pubitemid 26111202)
23. Y. Imai, H. Inoue, A. Kataoka, W. Hua-Qin, M. Masuda, T. Ikeda, K. Tsukita, M. Soda, T. Kodama, T. Fuwa, Y. Honda, S. Kaneko, S. Matsumoto, K. Wakamatsu, S. Ito, M. Miura, T. Aosaki, S. Itohara, and R. Takahashi Pael receptor is involved in dopamine metabolism in the nigrostriatal system Neurosci. Res. 59 2007 413 425 (Pubitemid 350007809)
24. 2+ exchange (NCX1) inhibition by SEA0400 J. Biol. Chem. 279 2004 7544 7553 (Pubitemid 38294633)
25. T. Kawasaki, Y. Ago, T. Kitao, T. Nashida, A. Takagi, K. Takuma, and T. Matsuda A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy] propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced neurotoxicity in mice Neuropharmacology 55 2008 654 660
26. T. Kawasaki, K. Ishihara, Y. Ago, A. Baba, and T. Matsuda Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum J. Pharmacol. Exp. Ther. 322 2007 274 281 (Pubitemid 46956378)
27. T. Kawasaki, K. Ishihara, Y. Ago, S. Nakamura, S. Itoh, A. Baba, and T. Matsuda Protective effect of the radical scavenger edaravone against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum Eur. J. Pharmacol. 542 2006 92 99 (Pubitemid 44066362)
28. 2+ influx triggers nitric oxide-induced cytotoxicity in cultured astrocytes Neurochem. Int. 57 2010 58 66
29. P. Klivenyi, O.A. Andreassen, R.J. Ferrante, E. Lancelot, D. Reif, and M.F. Beal Inhibition of neuronal nitric oxide synthase protects against MPTP toxicity Neuroreport 11 2000 1265 1268 (Pubitemid 30262970)
30. R. Kurosaki, Y. Muramatsu, M. Michimata, M. Matsubara, H. Kato, Y. Imai, Y. Itoyama, and T. Araki Role of nitric oxide synthase against MPTP neurotoxicity in mice Neurol. Res. 24 2002 655 662
31. 2+ exchange inhibitors in attenuating ischemia-reperfusion injury Can. J. Cardiol. 21 2005 509 516 (Pubitemid 40823604)
32. G.T. Liberatore, V. Jackson-Lewis, S. Vukosavic, A.S. Mandir, M. Vila, W.G. McAuliffe, V.L. Dawson, T.M. Dawson, and S. Przedborski Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease Nat. Med. 5 1999 1403 1409
33. X. Lin, D.J. Yang, W.Q. Cai, Q.Y. Zhao, Y.F. Gao, Q. Chen, and R. Wang Endomorphins, endogenous opioid peptides, provide antioxidant defense in the brain against free radical-induced damage Biochim. Biophys. Acta 1639 2003 195 202 (Pubitemid 37421427)
34. S. Love Oxidative stress in brain ischemia Brain Pathol. 9 1999 119 131 (Pubitemid 29056523)
35. 2+ transport Biochem. J. 406 2007 365 382 (Pubitemid 47425443)
36. 2+ exchanger, attenuates reperfusion injury in the in vitro and in vivo cerebral ischemic models J. Pharmacol. Exp. Ther. 298 2001 249 256 (Pubitemid 32574534)
37. R.T. Matthews, L. Yang, and M.F. Beal S-Methylthiocitrulline, a neuronal nitric oxide synthase inhibitor, protects against malonate and MPTP neurotoxicity Exp. Neurol. 143 1997 282 286 (Pubitemid 27148232)
38. M. Miloso, A. Scuteri, D. Foudah, and G. Tredici MAPKs as mediators of cell fate determination: an approach to neurodegenerative diseases Curr. Med. Chem. 15 2008 538 548 (Pubitemid 351516810)
39. B. Moreno-López, C.R. Sunico, and D. González-Forero NO orchestrates the loss of synaptic boutons from adult "sick" motoneurons: modeling a molecular mechanism Mol. Neurobiol. 43 2011 41 66
40. 2+ exchange activity by interferon-γ in cultured rat microglia J. Neurochem. 90 2004 784 791 (Pubitemid 39099959)
41. 2+ exchanger, attenuates sodium nitroprusside-induced apoptosis in cultured rat microglia Br. J. Pharmacol. 144 2005 669 679 (Pubitemid 40445615)
42. 2+ exchange inhibitor SEA0400 prevents nitric oxide-induced cytotoxicity in SH-SY5Y cells Neurochem. Int. 59 2011 51 58
43. 2+ exchanger transcripts and proteins in rat brain regions J. Comp. Neurol. 461 2003 31 48 (Pubitemid 36578595)
44. K.D. Philipson, and D.A. Nicoll Sodium-calcium exchange: a molecular perspective Annu. Rev. Physiol. 62 2000 111 133 (Pubitemid 30618258)
45. S. Przedborski, V. Jackson-Lewis, R. Yokoyama, T. Shibata, V.L. Dawson, and T.M. Dawson Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity Proc. Natl. Acad. Sci. U S A 93 1996 4565 4571
46. M. Sedelis, R.K. Schwarting, and J.P. Huston Behavioral phenotyping of the MPTP mouse model of Parkinson's disease Behav. Brain Res. 125 2001 109 125 (Pubitemid 33000449)
47. N. Stence, M. Waite, and M.E. Dailey Dynamics of microglial activation: a confocal time-lapse analysis in hippocampal slices Glia 33 2001 256 266 (Pubitemid 32219134)
48. S. Surendran, and S. Rajasankar Parkinson's disease: oxidative stress and therapeutic approaches Neurol. Sci. 31 2010 531 540
49. H. Watanabe, Y. Muramatsu, R. Kurosaki, M. Michimata, M. Matsubara, Y. Imai, and T. Araki Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: an immunohistological study Eur. Neuropsychopharmacol. 14 2004 93 104 (Pubitemid 38175426)
50. P.S. Whitton Inflammation as a causative factor in the aetiology of Parkinson's disease Br. J. Pharmacol. 150 2007 963 976 (Pubitemid 46628616)
51. D.C. Wu, V. Jackson-Lewis, M. Vila, K. Tieu, P. Teismann, C. Vadseth, D.K. Choi, H. Ischiropoulos, and S. Przedborski Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model of Parkinson disease J. Neurosci. 22 2002 1763 1771 (Pubitemid 35386294)
52. L. Zhang, V.L. Dawson, and T.M. Dawson Role of nitric oxide in Parkinson's disease Pharmacol. Ther. 109 2006 33 41 (Pubitemid 41740813)